SaurabhDahiyaMD

PubMed

• 1214 citations
  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
  Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
  Lancet. 2020-06-20
• 1 citations
  A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
  Djordje Atanackovic, Thierry Iraguha, Destiny Omili, Stephanie V Avila, Xiaoxuan Fan
  Cytotherapy. 2024-04-01
• 449 citations
  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
  Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi
  Journal of Clinical Oncology. 2020-05-13

Abstracts/Posters

• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018